Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City
- PMID: 19808768
- PMCID: PMC2758337
- DOI: 10.1136/bmj.b3928
Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City
Abstract
Objective: To evaluate the association of 2008-9 seasonal trivalent inactivated vaccine with cases of influenza A/H1N1 during the epidemic in Mexico.
Design: Frequency matched case-control study.
Setting: Specialty hospital in Mexico City, March to May 2009.
Participants: 60 patients with laboratory confirmed influenza A/H1N1 and 180 controls with other diseases (not influenza-like illness or pneumonia) living in Mexico City or the State of Mexico and matched for age and socioeconomic status.
Main outcome measures: Odds ratio and effectiveness of trivalent inactivated vaccine against influenza A/H1N1.
Results: Cases were more likely than controls to be admitted to hospital, undergo invasive mechanical ventilation, and die. Controls were more likely than cases to have chronic conditions that conferred a higher risk of influenza related complications. In the multivariate model, influenza A/H1N1 was independently associated with trivalent inactivated vaccine (odds ratio 0.27, 95% confidence interval 0.11 to 0.66) and underlying conditions (0.15, 0.08 to 0.30). Vaccine effectiveness was 73% (95% confidence interval 34% to 89%). None of the eight vaccinated cases died.
Conclusions: Preliminary evidence suggests some protection from the 2008-9 trivalent inactivated vaccine against pandemic influenza A/H1N1 2009, particularly severe forms of the disease, diagnosed in a specialty hospital during the influenza epidemic in Mexico City.
Conflict of interest statement
Competing interests: JLV-G and SPdeLR are employed by Laboratorios de Biológicos y Reactivos de México (BIRMEX).
Comment in
-
The future of influenza vaccines.BMJ. 2009 Oct 6;339:b4014. doi: 10.1136/bmj.b4014. BMJ. 2009. PMID: 19808769 No abstract available.
-
Seasonal vaccine and H1N1. Selection bias explains seasonal vaccine's protection.BMJ. 2009 Nov 24;339:b4972. doi: 10.1136/bmj.b4972. BMJ. 2009. PMID: 19934198 No abstract available.
Similar articles
-
Protection of trivalent inactivated influenza vaccine against hospitalizations among pandemic influenza A (H1N1) cases in Argentina.Vaccine. 2010 Jul 19;28(32):5288-91. doi: 10.1016/j.vaccine.2010.05.051. Epub 2010 Jun 10. Vaccine. 2010. PMID: 20541580
-
Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.BMJ. 2011 Feb 3;342:c7297. doi: 10.1136/bmj.c7297. BMJ. 2011. PMID: 21292718 Free PMC article.
-
Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel.PLoS One. 2010 May 19;5(5):e10722. doi: 10.1371/journal.pone.0010722. PLoS One. 2010. PMID: 20502705 Free PMC article.
-
Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses.Vaccine. 2012 May 2;30(21):3209-22. doi: 10.1016/j.vaccine.2012.02.048. Epub 2012 Mar 2. Vaccine. 2012. PMID: 22387221 Review.
-
MF59 adjuvanted seasonal and pandemic influenza vaccines.Yakugaku Zasshi. 2011;131(12):1733-41. doi: 10.1248/yakushi.131.1733. Yakugaku Zasshi. 2011. PMID: 22129867 Review.
Cited by
-
An Orf-Virus (ORFV)-Based Vector Expressing a Consensus H1 Hemagglutinin Provides Protection against Diverse Swine Influenza Viruses.Viruses. 2023 Apr 18;15(4):994. doi: 10.3390/v15040994. Viruses. 2023. PMID: 37112974 Free PMC article.
-
Quantifying the Persistence of Vaccine-Related T Cell Epitopes in Circulating Swine Influenza A Strains from 2013-2017.Vaccines (Basel). 2021 May 6;9(5):468. doi: 10.3390/vaccines9050468. Vaccines (Basel). 2021. PMID: 34066605 Free PMC article.
-
Seasonal Influenza Vaccine Impact on Pandemic H1N1 Vaccine Efficacy.Clin Infect Dis. 2019 May 17;68(11):1839-1846. doi: 10.1093/cid/ciy812. Clin Infect Dis. 2019. PMID: 30239636 Free PMC article.
-
The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway.Vaccine. 2018 Jun 14;36(25):3650-3665. doi: 10.1016/j.vaccine.2018.05.029. Vaccine. 2018. PMID: 29764680 Free PMC article.
-
Vaccines for preventing influenza in the elderly.Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD004876. doi: 10.1002/14651858.CD004876.pub4. Cochrane Database Syst Rev. 2018. PMID: 29388197 Free PMC article. Review.
References
-
- World Health Organization. Influenza A(H1N1)—update 58. 2009. www.who.int/csr/don/2009_07_06/en/index.html.
-
- Swine influenza A (H1N1) infection in two children—southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009;58:400-2. - PubMed
-
- World Health Organization. Swine flu illness in the United States and Mexico—update 2. 2009. www.who.int/csr/don/2009_04_26/en/index.html.
-
- World Health Organization. Swine flu illness in the United States and Mexico. 2009. www.who.int/csr/don/2009_04_24/en/index.html.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical